Showing results (1-10 of 137) with videos related to
Sort By:
Pageof 14
Statistics in Medicine|April 2, 2004
Interval-censored survival time data: confidence intervals for the non-parametric survivor functionRuth L Goodall, David T Dunn, Abdel G BabikerAntiviral Therapy|May 17, 2007
A virological benefit from an induction/maintenance strategy: the Forte trialDavid Asboe, Ian G Williams, Ruth L Goodall, et al.Antiviral Therapy|November 13, 2004
HIV drug resistance testing: is the evidence really there?David T Dunn, Diana M Gibb, Abdel G Babiker, et al.Current Opinion in HIV and AIDS|April 18, 2009
Considerations in the design of randomized controlled trials evaluating the optimal time to initiate antiretroviral therapy in previously untreated HIV-1-infected patientsAbdel G Babiker, Diana M GibbThe Journal of Antimicrobial Chemotherapy|February 5, 2017
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan AfricaRuth L Goodall, David T Dunn, Peter Nkurunziza, et al.Statistics in Medicine|February 3, 2004
Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatmentA Sarah Walker, Ian R White, Abdel G BabikerFrontiers in Plant Science|June 1, 2016
Identification of Striga hermonthica-Resistant Upland Rice Varieties in Sudan and Their Resistance PhenotypesHiroaki Samejima, Abdel G Babiker, Ahmed Mustafa, et al.BMC Medical Research Methodology|September 17, 2016
Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patientsOliver T Stirrup, Abdel G Babiker, Andrew J CopasPlos One|March 15, 2014
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trialCissy Kityo, Diana M Gibb, Charles F Gilks, et al.Antiviral Therapy|January 30, 2003
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)Diana M Gibb, A Sarah Walker, Steve Kaye, et al.Pageof 14